- Hansa Biopharma to host Q2 2024 interim results conference call
- Hansa Biopharma: increase in number of shares and votes
- Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
- Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
- Hansa Biopharma interim report January-March 2024
More ▼
Key statistics
On Friday, Hansa Biopharma AB (HNSA:STO) closed at 48.46, -13.31% below its 52-week high of 55.90, set on Jun 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 47.50 |
---|---|
High | 49.02 |
Low | 46.58 |
Bid | 48.46 |
Offer | 48.46 |
Previous close | 47.50 |
Average volume | 141.06k |
---|---|
Shares outstanding | 67.81m |
Free float | 63.72m |
P/E (TTM) | -- |
Market cap | 3.29bn SEK |
EPS (TTM) | -16.07 SEK |
Data delayed at least 15 minutes, as of Jul 05 2024 17:00 BST.
More ▼